Inhaled Nitric Oxide for Pulmonary Hypertension and Bronchopulmonary Dysplasia
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Inhaled nitric oxide (iNO) is an effective treatment for pulmonary hypertension (PH) in term
and near-term infants. Preterm infants are at risk for early PH that is associated with high
risk for bronchopulmonary dysplasia or death. In multiple clinical trials, iNO treatment was
not effective for BPD prevention. However, infants were not screened for PH and iNO treatment
was not targeted for PH. iNO treatment for PH in preterm infants is controversial due to lack
of evidence. The study team hypothesizes that early diagnosis of PH (72-96 hours of life) and
iNO treatment will decrease the incidence of death and bronchopulmonary dysplasia and improve
oxygenation in extremely preterm infants.
1. To determine if iNO treatment of extremely preterm infants with early pulmonary
hypertension as established with echocardiographic evidence at 72-96 hours of age will
decrease incidence of death or BPD.
2. To determine if iNO treatment of extremely preterm infants with early PH will decrease
the pulmonary artery pressure and improve oxygenation within 72 hours of intervention.